MedTrace Logo

Losartan for Patients With COVID-19 Not Requiring Hospitalization

NCT04311177 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 117

Last updated 2022-05-04

Study results available
· View outcomes & findings →

Summary

This is a multi-center, double-blinded study of COVID-19 infected patients randomized 1:1 to daily losartan or placebo for 10 days or treatment failure (hospital admission).

Conditions

  • Corona Virus Infection
  • Acute Respiratory Distress Syndrome
  • SARS-CoV Infection

Interventions

DRUG

Losartan

Losartan; 25 mg daily; oral administration

OTHER

Placebo

Placebo (microcrystalline methylcellulose, gelatin capsule); oral administration

Sponsors & Collaborators

Principal Investigators

  • Christopher Tignanelli, MD · University of Minnesota

  • Michael Puskarich, MD, MS · University of Minnesota

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-04-09
Primary Completion
2021-02-01
Completion
2021-02-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04311177 on ClinicalTrials.gov